Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles

Srinivas Ramishetti, Ranit Kedmi, Meir Goldsmith, Fransisca Leonard, Andrew G. Sprague, Biana Godin, Michael Gozin, Pieter R. Cullis, Derek M Dykxhoorn, Dan Peer

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Modulating T cell function by down-regulating specific genes using RNA interference (RNAi) holds tremendous potential in advancing targeted therapies in many immune-related disorders including cancer, inflammation, autoimmunity, and viral infections. Hematopoietic cells, in general, and primary T lymphocytes, in particular, are notoriously hard to transfect with small interfering RNAs (siRNAs). Herein, we describe a novel strategy to specifically deliver siRNAs to murine CD4<sup>+</sup> T cells using targeted lipid nanoparticles (tLNPs). To increase the efficacy of siRNA delivery, these tLNPs have been formulated with several lipids designed to improve the stability and efficacy of siRNA delivery. The tLNPs were surface-functionalized with anti-CD4 monoclonal antibody to permit delivery of the siRNAs specifically to CD4<sup>+</sup> T lymphocytes. Ex vivo, tLNPs demonstrated specificity by targeting only primary CD4<sup>+</sup> T lymphocytes and no other cell types. Systemic intravenous administration of these particles led to efficient binding and uptake into CD4<sup>+</sup> T lymphocytes in several anatomical sites including the spleen, inguinal lymph nodes, blood, and the bone marrow. Silencing by tLNPs occurs in a subset of circulating and resting CD4<sup>+</sup> T lymphocytes. Interestingly, we show that tLNP internalization and not endosome escape is a fundamental event that takes place as early as 1 h after systemic administration and determines tLNPs' efficacy. Taken together, these results suggest that tLNPs may open new avenues for the manipulation of T cell functionality and may help to establish RNAi as a therapeutic modality in leukocyte-associated diseases.

Original languageEnglish (US)
Pages (from-to)6706-6716
Number of pages11
JournalACS Nano
Volume9
Issue number7
DOIs
StatePublished - Jul 28 2015

Fingerprint

T-cells
lymphocytes
genes
Lipids
lipids
Genes
Nanoparticles
nanoparticles
RNA
Small Interfering RNA
delivery
interference
leukocytes
spleen
Monoclonal antibodies
bone marrow
lymphatic system
infectious diseases
cells
antibodies

Keywords

  • CD45
  • lipid-based nanoparticles
  • RNA interference
  • T lymphocytes

ASJC Scopus subject areas

  • Engineering(all)
  • Materials Science(all)
  • Physics and Astronomy(all)

Cite this

Ramishetti, S., Kedmi, R., Goldsmith, M., Leonard, F., Sprague, A. G., Godin, B., ... Peer, D. (2015). Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles. ACS Nano, 9(7), 6706-6716. https://doi.org/10.1021/acsnano.5b02796

Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles. / Ramishetti, Srinivas; Kedmi, Ranit; Goldsmith, Meir; Leonard, Fransisca; Sprague, Andrew G.; Godin, Biana; Gozin, Michael; Cullis, Pieter R.; Dykxhoorn, Derek M; Peer, Dan.

In: ACS Nano, Vol. 9, No. 7, 28.07.2015, p. 6706-6716.

Research output: Contribution to journalArticle

Ramishetti, S, Kedmi, R, Goldsmith, M, Leonard, F, Sprague, AG, Godin, B, Gozin, M, Cullis, PR, Dykxhoorn, DM & Peer, D 2015, 'Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles', ACS Nano, vol. 9, no. 7, pp. 6706-6716. https://doi.org/10.1021/acsnano.5b02796
Ramishetti S, Kedmi R, Goldsmith M, Leonard F, Sprague AG, Godin B et al. Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles. ACS Nano. 2015 Jul 28;9(7):6706-6716. https://doi.org/10.1021/acsnano.5b02796
Ramishetti, Srinivas ; Kedmi, Ranit ; Goldsmith, Meir ; Leonard, Fransisca ; Sprague, Andrew G. ; Godin, Biana ; Gozin, Michael ; Cullis, Pieter R. ; Dykxhoorn, Derek M ; Peer, Dan. / Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles. In: ACS Nano. 2015 ; Vol. 9, No. 7. pp. 6706-6716.
@article{b41f9b8a5f7940fa8bda1dd38620234f,
title = "Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles",
abstract = "Modulating T cell function by down-regulating specific genes using RNA interference (RNAi) holds tremendous potential in advancing targeted therapies in many immune-related disorders including cancer, inflammation, autoimmunity, and viral infections. Hematopoietic cells, in general, and primary T lymphocytes, in particular, are notoriously hard to transfect with small interfering RNAs (siRNAs). Herein, we describe a novel strategy to specifically deliver siRNAs to murine CD4+ T cells using targeted lipid nanoparticles (tLNPs). To increase the efficacy of siRNA delivery, these tLNPs have been formulated with several lipids designed to improve the stability and efficacy of siRNA delivery. The tLNPs were surface-functionalized with anti-CD4 monoclonal antibody to permit delivery of the siRNAs specifically to CD4+ T lymphocytes. Ex vivo, tLNPs demonstrated specificity by targeting only primary CD4+ T lymphocytes and no other cell types. Systemic intravenous administration of these particles led to efficient binding and uptake into CD4+ T lymphocytes in several anatomical sites including the spleen, inguinal lymph nodes, blood, and the bone marrow. Silencing by tLNPs occurs in a subset of circulating and resting CD4+ T lymphocytes. Interestingly, we show that tLNP internalization and not endosome escape is a fundamental event that takes place as early as 1 h after systemic administration and determines tLNPs' efficacy. Taken together, these results suggest that tLNPs may open new avenues for the manipulation of T cell functionality and may help to establish RNAi as a therapeutic modality in leukocyte-associated diseases.",
keywords = "CD45, lipid-based nanoparticles, RNA interference, T lymphocytes",
author = "Srinivas Ramishetti and Ranit Kedmi and Meir Goldsmith and Fransisca Leonard and Sprague, {Andrew G.} and Biana Godin and Michael Gozin and Cullis, {Pieter R.} and Dykxhoorn, {Derek M} and Dan Peer",
year = "2015",
month = "7",
day = "28",
doi = "10.1021/acsnano.5b02796",
language = "English (US)",
volume = "9",
pages = "6706--6716",
journal = "ACS Nano",
issn = "1936-0851",
publisher = "American Chemical Society",
number = "7",

}

TY - JOUR

T1 - Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles

AU - Ramishetti, Srinivas

AU - Kedmi, Ranit

AU - Goldsmith, Meir

AU - Leonard, Fransisca

AU - Sprague, Andrew G.

AU - Godin, Biana

AU - Gozin, Michael

AU - Cullis, Pieter R.

AU - Dykxhoorn, Derek M

AU - Peer, Dan

PY - 2015/7/28

Y1 - 2015/7/28

N2 - Modulating T cell function by down-regulating specific genes using RNA interference (RNAi) holds tremendous potential in advancing targeted therapies in many immune-related disorders including cancer, inflammation, autoimmunity, and viral infections. Hematopoietic cells, in general, and primary T lymphocytes, in particular, are notoriously hard to transfect with small interfering RNAs (siRNAs). Herein, we describe a novel strategy to specifically deliver siRNAs to murine CD4+ T cells using targeted lipid nanoparticles (tLNPs). To increase the efficacy of siRNA delivery, these tLNPs have been formulated with several lipids designed to improve the stability and efficacy of siRNA delivery. The tLNPs were surface-functionalized with anti-CD4 monoclonal antibody to permit delivery of the siRNAs specifically to CD4+ T lymphocytes. Ex vivo, tLNPs demonstrated specificity by targeting only primary CD4+ T lymphocytes and no other cell types. Systemic intravenous administration of these particles led to efficient binding and uptake into CD4+ T lymphocytes in several anatomical sites including the spleen, inguinal lymph nodes, blood, and the bone marrow. Silencing by tLNPs occurs in a subset of circulating and resting CD4+ T lymphocytes. Interestingly, we show that tLNP internalization and not endosome escape is a fundamental event that takes place as early as 1 h after systemic administration and determines tLNPs' efficacy. Taken together, these results suggest that tLNPs may open new avenues for the manipulation of T cell functionality and may help to establish RNAi as a therapeutic modality in leukocyte-associated diseases.

AB - Modulating T cell function by down-regulating specific genes using RNA interference (RNAi) holds tremendous potential in advancing targeted therapies in many immune-related disorders including cancer, inflammation, autoimmunity, and viral infections. Hematopoietic cells, in general, and primary T lymphocytes, in particular, are notoriously hard to transfect with small interfering RNAs (siRNAs). Herein, we describe a novel strategy to specifically deliver siRNAs to murine CD4+ T cells using targeted lipid nanoparticles (tLNPs). To increase the efficacy of siRNA delivery, these tLNPs have been formulated with several lipids designed to improve the stability and efficacy of siRNA delivery. The tLNPs were surface-functionalized with anti-CD4 monoclonal antibody to permit delivery of the siRNAs specifically to CD4+ T lymphocytes. Ex vivo, tLNPs demonstrated specificity by targeting only primary CD4+ T lymphocytes and no other cell types. Systemic intravenous administration of these particles led to efficient binding and uptake into CD4+ T lymphocytes in several anatomical sites including the spleen, inguinal lymph nodes, blood, and the bone marrow. Silencing by tLNPs occurs in a subset of circulating and resting CD4+ T lymphocytes. Interestingly, we show that tLNP internalization and not endosome escape is a fundamental event that takes place as early as 1 h after systemic administration and determines tLNPs' efficacy. Taken together, these results suggest that tLNPs may open new avenues for the manipulation of T cell functionality and may help to establish RNAi as a therapeutic modality in leukocyte-associated diseases.

KW - CD45

KW - lipid-based nanoparticles

KW - RNA interference

KW - T lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=84938152114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938152114&partnerID=8YFLogxK

U2 - 10.1021/acsnano.5b02796

DO - 10.1021/acsnano.5b02796

M3 - Article

C2 - 26042619

AN - SCOPUS:84938152114

VL - 9

SP - 6706

EP - 6716

JO - ACS Nano

JF - ACS Nano

SN - 1936-0851

IS - 7

ER -